NASDAQ$THRD
Third Harmonic Bio Inc · Q4 2023 earnings
Q4 2023 earnings · · Investor relations
Briefing
Financial results for the fourth quarter and full year 2023 were announced.
Third Harmonic Bio reported a net loss of $6.8 million for the fourth quarter of 2023, with cash and cash equivalents totaling $269.1 million as of December 31, 2023. The company believes its cash will fund operations through at least 2026.
- U.S. IND was filed for THB335, with clinical trial start anticipated during Q2 2024.
- Cash and cash equivalents totaled $269.1 million as of December 31, 2023.
- R&D expenses decreased to $5.9 million for the three months ended December 31, 2023.
- Net loss for the three months ended December 31, 2023 decreased to $6.8 million.
Headline financials
Revenue & EPS history
Third Harmonic · Revenue · Quarterly
$836K
Forward guidance
Third Harmonic Bio anticipates clinical trials for THB335 to start in Q2 2024 and believes its existing cash and cash equivalents will be sufficient to fund its operating expenses and capital expenditure requirements through at least 2026.
Tailwinds
- Clinical trials for THB335 are expected to start in Q2 2024.
- Cash and cash equivalents are sufficient to fund operations through at least 2026.
Headwinds
- Numerous risks and uncertainties could cause actual results to differ materially.
- Risks related to cash forecasts.
- Risks in advancing product candidates.
- Risks related to potential regulatory submissions.
- Risks in changes to laws or regulations.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 5 quarterly earnings reports
+1.0%
Avg return
Earnings day
+14.2%
Avg return
5 days after
+13.0%
Avg return
30 days after
40%
6 / 15 earnings
Positive
+13.0%
Q3 2024
Best reaction
-11.1%
Q1 2023
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q2 2025 | — | — | — | |
| Q1 2025 | +0.6% | -0.2% | +5.8% | |
| Q4 2024 | -1.1% | +42.1% | +41.9% | |
| Q3 2024 | +13.0% | +13.0% | -11.2% | |
| Q2 2024 | +10.6% | +11.5% | +9.2% | |
| Q1 2024 | +10.2% | +11.8% | +3.3% | |
| Q4 2023 | +8.0% | +7.1% | +29.2% | |
| Q3 2023 | +0.8% | — | — | |
| Q2 2023 | -6.4% | — | — | |
| Q1 2023 | -11.1% | — | — | |
| Q4 2022 | -3.5% | — | — | |
| Q3 2021 | -1.2% | — | — | |
| Q4 2021 | -1.2% | — | — | |
| Q3 2022 | -1.2% | — | — | |
| Q1 2022 | -1.2% | — | — | |
| Q2 2022 | -1.2% | — | — | |
| Q2 2021 | — | — | — | |
| Q1 2021 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro